SWAN is pleased to announce a follow-on investment in NexPlasmaGen, which is developing noninvasive cold plasma technology designed to kill residual cancer cells following tumor removal and reduce the risk of breast cancer recurrence. SWAN members first invested in NexPlasmaGen in June 2025.